FSHD UK
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Ruth Hereford shared this information on a research funded by Canada (also a member of Project Mercury)
Neil Camarta (FSHD Canada) shared this research with us on muscle regeneration
Yusuke Nishimura who is part of the Research team has recently had a paper published
At the kind invitation of Dr. Alberto Malerba, Lecturer in Gene Therapy at the Royal Holloway, University of London, Rajeshri Badiani presented the FSHD UK journey
In October 2023 Rajeshri (aka ‘Raj’ ) Badiani was interviewed by Kristi Clark, VP – Clinical Operations, Avidity Biosciences on Raj’s FSHD journey and her work on FSHD UK especially in progressing clinical trials in the UK.